Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danyelza and GM-CSF in relapsed/refractory high-risk neuroblastoma
NCT01757626Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2012
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 2 trial of naxitamab in neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2012; status: active, not recruiting.
02
Drugs
naxitamab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT01757626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01757626.